Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal
Dexcom Inc DXCM
$86.64
▼ -0.05%
($-0.04)
Index member:
S&P 500
Open
$86.63
Prev Close
$86.68
Day Range
$85.24 – $87.03
52W Range
$54.11 – $92.59
Market Cap
$33.01B
P/E (TTM)
32.48
Beta
1.45
EPS (TTM)
$2.51
📋 Company Profile
| Industry | Health Care |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2005-04-14 |
| Shares Out. | 385,870,000 |
| Website | dexcom.com/ ↗ |
| Phone | 13026365400 |
| Employees | 11,100 |
| Revenue | $1.31B |
| Gross Profit | $830.0M |
| Net Income | $249.1M |
| Free Cash Flow | $1.41B |
| Total Assets | $6.46B |
| Total Liabilities | $3.83B |
| Equity | $2.62B |
About Dexcom Inc
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
Dexcom Inc is a publicly traded company under the ticker symbol DXCM on the NASDAQ NMS - GLOBAL MARKET, operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
36 analysts (2026-09-01)
📰 Latest News for DXCM
This Stock Could Be the Big Winner Out of Oura’s IPO
The Insider Report: The Leaders Have Taken Off
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets
Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
Dexcom Becomes Team Novo Nordisk's Official CGM Partner, Releases Report Citing Three Type 2 Care Challenges Across Eight Countries
2 Large-Cap Stocks with Exciting Potential and 1 Facing Headwinds
DexCom (DXCM) Stock Looks Cheap Based On Future Cash Flow